This page shows the latest Pronova news and features for those working in and with pharma, biotech and healthcare.
Once launched Epanova will enter a competitive for market for hypertriglyceridemia medicines, including BASF/Pronova's Omacor/Lovaza, another omega-3 fatty acid product.
GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over Reliant Pharmaceuticals in 2008 for $1.7bn. ... An earlier settlement between ProNova and Apotex gave the generics company rights to
There is competition in the hypertriglyceridemia area, however, and if approved, Epanova would compete in the marketplace against BASF/Pronova's Omacor/Lovaza, an omega-3 fatty acid product that achieved
weeks. If approved, Epanova would compete in the marketplace against BASF/Pronova's Omacor/Lovaza, an omega-3 fatty acid product that achieved end-user sales of around $1.4bn in
originator Pronova BioPharma of Norway.
The drug, the US rights of which were in-licensed from Norway-based Pronova BioPharma, is indicated as an adjunct to diet. ... Pronova will continue to supply the product's primary material. Rights to Lovaza in other markets have been licensed by the
More from news
Approximately 0 fully matching, plus 6 partially matching documents found.
that corresponds to a 24 per cent premium on Pronova's average six month share price and values the company at about 5.7 times annual earnings. ... 900. Pronova BioPharma / BASF. Acquisition. Omega-3 fatty acids. Active ingredient for Lovaza, p
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...